Layne N. Raborn

Dr. Layne N. Raborn

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


30 April 2024 in Cells
Verified
Journal Article
Open access
PDF file
ZMZachary Michel
Zachary Michel
LRLayne N. Raborn
Layne N. Raborn
TSTiahna Spencer
Tiahna Spencer
KPKristen S. Pan
Kristen S. Pan
DMDaniel Martin
Daniel Martin
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
Fibrous dysplasia (FD) is a mosaic skeletal disorder caused by somatic activating variants of GNAS encoding for Gαs and leading to excessive cyclic adenosine monophosphate signaling in bone-marrow stromal cells (BMSCs). The effect of Gαs activation in the BMSC transcriptome and how it influences FD lesion microenvironment are unclear. We analyzed changes induced by Gαs activation in the BMSC transcriptome and secretome. RNAseq analysis of differential gene expression of cultured BMSCs from patients with FD and healthy volunteers, and from an inducible mouse model of FD, was performed, and the transcriptomic profiles of both models were combined to build a robust FD BMSC genetic signature. Pathways related to Gαs activation, cytokine signaling, and extracellular matrix deposition were identified. To assess the modulation of several key secreted factors in FD pathogenesis, cytokines and other factors were measured in culture media. Cytokines were also screened in a collection of plasma samples from patients with FD, and positive correlations of several cytokines to their disease burden score, as well as to one another and bone turnover markers, were found. These data support the pro-inflammatory, pro-osteoclastic behavior of FD BMSCs and point to several cytokines and other secreted factors as possible therapeutic targets and/or circulating biomarkers for FD.

21 February 2024 in Journal of Surgical Education
Verified
Journal Article
Closed access
LRLayne N. Raborn
Layne N. Raborn
RERami Elmorsi
Rami Elmorsi
BSBrandon T. Smith
Brandon T. Smith
MAMalke Asaad
Malke Asaad
RKRebecca Kelley
Rebecca Kelley
FEFrancesco M Egro
Francesco M Egro

16 December 2024 in Journal of Surgical Education
Verified
Journal Article
Closed access
RERami Elmorsi
Rami Elmorsi
LRLayne N. Raborn
Layne N. Raborn
BSBrandon T. Smith
Brandon T. Smith
MAMalke Asaad
Malke Asaad
FEFrancesco M Egro
Francesco M Egro

28 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ZMZachary Michel
Zachary Michel
LRLayne N. Raborn
Layne N. Raborn
TSTiahna Spencer
Tiahna Spencer
KPKristen Pan
Kristen Pan
DMDaniel Martin
Daniel Martin
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
Fibrous dysplasia (FD) is a mosaic skeletal disorder caused by somatic activating variants in GNAS , encoding for Gα s , which leads to excessive cAMP signaling in bone marrow stromal cells (BMSCs). Despite advancements in our understanding of FD pathophysiology, the effect of Gα s activation in the BMSC transcriptome remains unclear, as well as how this translates into their local influence in the lesional microenvironment. In this study, we analyzed changes induced by Gα s activation in BMSC transcriptome and performed a comprehensive analysis of their production of cytokines and other secreted factors. We performed RNAseq of cultured BMSCs from patients with FD and healthy volunteers, and from an inducible mouse model of FD, and combined their transcriptomic profiles to build a robust FD BMSC genetic signature. Pathways related to Gα s activation, cytokine signaling, and extracellular matrix deposition were identified. In addition, a comprehensive profile of their secreted cytokines and other factors was performed to identify modulation of several key factors we hypothesized to be involved in FD pathogenesis. We also screened circulating cytokines in a collection of plasma samples from patients with FD, finding positive correlations of several cytokines to their disease burden score, as well as to one another and bone turnover markers. Overall, these data support a pro-inflammatory, pro-osteoclastic behavior of BMSCs bearing hyperactive Gα s variants, and point to several cytokines and other secreted factors as possible therapeutic targets and/or circulating biomarkers for FD.